Prospects Fund

Prospects Oncology Fund

prospect-oncology-fund-imgFACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Investment Strategy and have the potential to act as deal flow for the IPDC Fund. Awarded grants typically range between $50,000 and $200,000.

Funding is governed by a research contract which grants certain rights to FACIT.   FACIT receives no financial consideration on Prospects grants under $100,000.  On grants of $100,000 or more, FACIT receives an option to make an investment at the IPDC level and act as the agent for commercialization.  If the option is exercised, funding received from the Prospects grant will be credited towards FACIT's IPDC investment.

How to apply:

The Prospects Fund is accepting pre-submission forms twice yearly on the following dates:

  • March 31
  • September 30

The pre-submission form can be downloaded here.

Late applications will not be considered.

Selected applicants will then be invited to prepare a Prospects funding application which is subject to due diligence by FACIT.

Select Prospects Funded Projects

Prospects Fund (Other)

ADC Linker Platform

Further development of novel cyclic and heterocyclic hydrazone-based linkers for antibody-drug-conjugates (ADC).

ADC Linker PlatformADC Linker Platform


Test to Predict Breast Cancer Patient Response to Anthracyclines

Further validation of novel diagnostic gene test to predict which patients benefit from anthracycline chemotherapy.

Test to Predict Breast Cancer Patient Response to AnthracyclinesTest to Predict Breast Cancer Patient Response to Anthracyclines


Automatic Analysis of Screening Mammograms for Breast Cancer

Clinical validation of a novel breast cancer screening algorithm that can identify select screening mammograms as ‘benign and requiring no further review’, thereby reducing the need for a radiologi

Automatic Analysis of Screening Mammograms for Breast CancerAutomatic Analysis of Screening Mammograms for Breast Cancer


DT1 Class of Agents for the Treatment of AML and Other Orphan Cancers

Development of DT-1 class of small molecules which possess selective cancer cell-killing activity and reduced toxicity due to a unique “cloaking” mechanism.

DT1 Class of Agents for the Treatment of AML and Other Orphan CancersDT1 Class of Agents for the Treatment of AML and Other Orphan Cancers


View All Prospects Funded Projects